| Literature DB >> 21822857 |
Dominik Stodulski1, Boguslaw Mikaszewski, Czeslaw Stankiewicz.
Abstract
The aim of his study was to assess the treatment results and prognostic factors in patients with parotid gland carcinoma. The material consisted of 109 patients treated surgically, with or without complementary radiotherapy, between 1978 and 2008 (follow-up at least 5-years). 5-year overall and disease-specific survival were observed in 57.0% of the patients and 5-year disease-free survival was achieved in 50.0%. Univariate analysis including ten clinical and pathological features to assess their prognostic value was done. Parapharyngeal space invasion, facial nerve palsy, and high grade of tumor malignancy were the factors with the highest influence on the treatment results, because their presence decreased the chance for recovery 9.8, 9.7, and 8.2 times, respectively. Histologically positive cervical lymph nodes and extraparenchymal extension were the other factors connected with poor prognosis (prognosis worse 6.7 and 5.4 times, respectively). Clinically positive cervical lymph nodes, positive/uncertain microscopic margin, involvement of the deep lobe, or the whole gland increased the risk of treatment failure 3.4, 3.1, and 2.8, respectively. The age ≥ 60 years and male gender were statistically significant factors, correlated with poor prognosis and decreased chance for recovery 2.4 and 2.6 times. T-status and clinical stage had important influence on 5-year disease-free survival rate because there were significant differences in the treatment results between individual stages. Multivariate analysis proved that the independent prognostic value, among anatomic structures involved by the neoplasm, had mandible, facial nerve, and skin infiltration. Among tumor-related factors, T-stage and grade had the statistically significant influence on treatment results, and stage and lymph nodes metastases among clinical and pathological features. These results confirm the value of actually used TNM classification (2002). Although the parapharyngeal space invasion is a factor, which seems to have a significant, poor prognostic value, it was not included in this classification.Entities:
Mesh:
Year: 2011 PMID: 21822857 PMCID: PMC3275734 DOI: 10.1007/s00405-011-1716-6
Source DB: PubMed Journal: Eur Arch Otorhinolaryngol ISSN: 0937-4477 Impact factor: 2.503
T stage of the major salivary glands
| T1 | Tumor 2 cm or less in greatest dimension without extraparenchymal extension |
| T2 | Tumor more than 2 cm but not more than 4 cm in greatest dimension without extraparenchymal extension |
| T3 | Tumor more than 4 cm and/or tumor having extraparenchymal extension |
| T4a | Tumor invades skin, mandible, ear canal, or facial nerve |
| T4b | Tumor invades base of skull, pterygoid plates, or encases carotid artery |
TNM classification (UICC 2002)
Extraparenchymal extension is clinical or macroscopic evidence of invasion of soft tissues or nerve, except these listed under T4a and T4b. Microscopic evidence alone does not constitute extraparenchymal extension for classification purposes
5-, 10-, 15-year overall survival, disease-specific survival, disease-free survival in patients with parotid gland carcinoma
| 5-year (%) | 10-year (%) | 15-year (%) | |
|---|---|---|---|
| Overall survival | 57.0 | 34.0 | 24.0 |
| Disease-specific survival | 57.0 | 51.0 | 45.0 |
| Disease-free survival | 50.0 | 41.0 | 38.0 |
Fig. 1Overall survival, disease-specific survival, disease-free survival (diagonal lines on the survival curves indicate censored observations)
Fig. 2Treatment results according to the presence of the parapharyngeal space invasion
5-year disease-free survival according to selected clinical and pathological variables in univariate analysis
| 5-year disease-free survival (%) | Odds ratio | 95% confidence interval |
| |
|---|---|---|---|---|
| Parapharyngeal space invasion | 11.8 | 9.8 | 2.1–45.1 | 0.0007 |
| Facial nerve paresis/paralysis | 13.0 | 9.7 | 2.7–35.2 | 0.0008 |
| High grade | 35.5 | 8.2 | 3.0–22.2 | 0.0001 |
| Histologically positive cervical lymph nodes | 18.9 | 6.7 | 2.5–18.1 | 0.0007 |
| Extraparenchymal extension | 28.0 | 5.4 | 2.4–12.3 | 0.0003 |
| Clinically positive cervical lymph nodes | 29.4 | 3.4 | 1.4–8.1 | 0.005 |
| Positive microscopic margin | 30.0 | 3.1 | 1.3–7.6 | 0.012 |
| Deep lobe/whole gland | 38.3 | 2.8 | 1.3–6.0 | 0.009 |
| Male gender | 37.7 | 2.6 | 1.2–5.5 | 0.016 |
| Age (≥60 years) | 38.9 | 2.4 | 1.1–5.1 | 0.027 |
Multivariate analysis
| Hazard ratio | 95% confidence interval |
| |
|---|---|---|---|
| Mandible invasion | 4.13 | 1.22–13.92 | 0.022 |
| Facial nerve invasion | 2.38 | 1.38–4.11 | 0.002 |
| Skull base invasion | 2.25 | 0.45–11.26 | 0.323 |
| Skin invasion | 2.04 | 1.04–4.00 | 0.037 |
| Parapharyngeal space invasion | 1.76 | 0.86–3.57 | 0.120 |
| Masseter muscle invasion | 1.52 | 0.80–2.89 | 0.202 |
| External auditory canal invasion | 1.06 | 0.40–2.79 | 0.909 |
Association of anatomical structures involved by the neoplasm with recovery
Multivariate analysis
| Hazard ratio | 95% confidence interval |
| |
|---|---|---|---|
| T stage | 1.78 | 1.29–2.45 | 0.0005 |
| N stage | 1.48 | 0.84–2.61 | 0.170 |
| Tumor grade | 1.47 | 1.12–1.92 | 0.006 |
Association of tumor related factors with recovery
Multivariate analysis
| Hazard Ratio | 95% Confidence Interval |
| |
|---|---|---|---|
| Age ≥ 60 years | 1.02 | 1.00–1.04 | 0.018 |
| Male gender | 1.58 | 0.90–2.79 | 0.114 |
| Clinical stage | 1.82 | 1.26–2.62 | 0.001 |
| Histologically positive cervical lymph nodes | 2.29 | 1.26–4.14 | 0.006 |
| Positive/uncertain microscopic margin | 1.06 | 0.83–1.55 | 0.747 |
Association of selected clinical and pathological variables with recovery